ADHD
White House assembles top minds in neuroscience and learning for workshop
Feb. 3, 2015—Vanderbilt's Laurie Cutting was one of a select group of experts in neuroscience, cognitive science, developmental psychology and other disciplines invited to take part in a White House Office of Science and Technology Policy workshop.
‘Darting’ mice may hold clues to ADHD, autism and bipolar disorder
Oct. 23, 2014—The transgenic mouse, into which was inserted a rare human genetic variation in the dopamine transporter, could lead to improvements in the diagnosis and treatment of these all-too-common brain disorders.
U.S. Senate hearing explores ADHD treatment concerns
Feb. 27, 2014—William Cooper, M.D., MPH, Cornelius Vanderbilt Professor of Pediatrics and Health Policy, testified Tuesday before the U.S. Senate Health, Education, Labor and Pensions (HELP) committee regarding psychotropic medications and treatments for Attention Deficit Hyperactivity Disorder (ADHD).
Neurotransmitter’s role in bone balance
Nov. 7, 2013—Removal of the neurotransmitter norepinephrine from the space outside cells plays an important role in the regulation of bone remodeling.
Transporter linked to autism risk
Sep. 19, 2013—Vanderbilt University investigators for the first time have linked a non-inherited, de novo mutation in the dopamine transporter to autism spectrum disorder (ASD).
Antipsychotic drug use in children for mood/behavior disorders increases type 2 diabetes risk
Aug. 22, 2013—Prescribing “atypical” antipsychotic medications to children and young adults with behavioral problems or mood disorders may put them at unnecessary risk for type 2 diabetes, a Vanderbilt University Medical Center study shows.
New clue to ADHD
May. 15, 2012—A rare genetic change adds support to the idea that altered dopamine signaling is a key risk factor for ADHD.
Minds wide open: Neuroscience at Vanderbilt
Apr. 6, 2012—Vanderbilt University has emerged as one of the nation’s leading academic centers in neuroscience.
Study finds no heart risk with ADHD drugs
Nov. 3, 2011—Attention deficit hyperactivity disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.
Vanderbilt study finds no heart risk in ADHD medications
Nov. 2, 2011—Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.
New insight into impulse control
Aug. 30, 2011—How the brain is wired to control impulsive behavior differs significantly from what psychologists have thought, new research finds.